Review: Omalizumab reduces asthma exacerbations and daily steroid use

January 2004
ACP Journal Club;Jan/Feb2004, Vol. 140 Issue 1, p13
Academic Journal
This article focuses on a study regarding anti-immunoglobulin E for chronic asthma, published in the 2003 issue of the journal "Cochrane Database of Systematic Reviews." For this study the researchers selected studies if they were randomized controlled trials comparing anti-immunoglobulin E at any dose or route with placebo or conventional treatments. Main outcomes were reduction or termination of steroid use and asthma exacerbations. 8 blinded, placebo-controlled trials met the inclusion criteria. Omalizumab drug was administered by inhaler in 1 trial, intravenously in 3 trials, and subcutaneously in 4 trials. The study concluded that in patients with asthma, intravenous or subcutaneous omalizumab reduces asthma exacerbations when used as adjunctive or steroid-sparing therapy and reduces inhaled steroid use.


Related Articles

  • Review: Omalizumab reduces asthma exacerbations and daily steroid use: COMMENTARY. Thien, Frank // ACP Journal Club;Jan/Feb2004, Vol. 140 Issue 1, p13 

    This article focuses on a study regarding anti-immunoglobulin E for chronic asthma, published in the 2003 issue of the journal "Cochrane Database of Systematic Reviews." The role of monoclonal anti-immunoglobulin E antibodies in clinical asthma management continues to evolve. The meta-analysis...

  • Detailed postal feedback about prescribing to asthma patients combined with a guideline statement showed no impact: a randomised controlled trial. Søndergaard, Jens; Andersen, Morten; Vach, Kirstin; Kragstrup, Jakob; Maclure, Malcolm; Gram, Lars F. // European Journal of Clinical Pharmacology;May2002, Vol. 58 Issue 2, p127 

    Objective. To evaluate the effects of postal feedback with clinically relevant data on general practitioners' prescribing compared with feedback with aggregate data on prescribing patterns of asthma drugs. Methods. The study was a randomised, controlled trial. The general practitioners (GPs) in...

  • Swimming in Allergens? Spivey, Angela // Environmental Health Perspectives;Oct2006, Vol. 114 Issue 10, pA600 

    The article reports that regular exposure to indoor chlorinated swimming pools may contribute to atopic asthma. Atopic asthma is a predisposition to atopy, which is the hypersensitivity to certain antigens called allergens. Atopic individuals produce abnormally high levels of the antibody...

  • Inhaled corticosteroids were safely stepped down in chronic, stable asthma.  // ACP Journal Club;Jan/Feb2004, Vol. 140 Issue 1, p14 

    This article focuses on a study regarding the use of inhaled corticosteroids in asthma patients, published in the 2003 issue of "British Medical Journal." For this study a clinical trial of 259 patients was conducted. Patients were allocated to a step-down group or a control group. All patients...

  • A randomised trial of seIf-management planning for adult patients admitted to hospital with acute asthma. Osman, L. M.; Calder, C.; Godden, D. J.; Friend, J. A. R.; Mckenzie, L.; Legge, J. S.; Douglas, J. G. // Thorax;Oct2002, Vol. 57 Issue 10, p869 

    Background: There is still debate over the benefit of sell-management programmes for adults with asthma. A brief self-management programme given during a hospital admission for acute asthma was tested to determine whether it would reduce readmission. Method: A randomised controlled trial was...

  • Doubling the dose of budesonide versus maintainance treatment in asthma exacerbations. Filzgerald, J. M.; Becker, A.; Sears, M. R.; Mink, S.; Chung, K.; Lee, J. // Thorax;Jul2004, Vol. 59 Issue 7, p550 

    Background: Previous guidelines recommend doubling the daily dose of maintenance inhaled corticosteroid to treat or prevent progression of exacerbations of asthma. Methods: Over a 6 month period a cohort of patients were evaluated prospectively and randomised in a double blind controlled trial...

  • Anti-Immunoglobulin E Treatment with Omalizumab in Allergic Diseases an Update on Anti-Inflammatory Activity and Clinical Efficacy. Olcay, I. // Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry;Feb2008, Vol. 7 Issue 1, p27 

    Omalizumab is recently developed monoclonal anti-IgE antibody. Clinical trials have demonstrated its efficacy in patients with moderate-to-severe and severe or poorly controlled allergic asthma, in patients with seasonal and perennial allergic disease and in subjects with concomitant asthma and...

  • Inhaled steroids are best at lower doses. Duerden, Martin // GP: General Practitioner;6/30/2003, p32 

    Inhaled steroids are an essential part of asthma treatment for many patients. However, it has become increasingly apparent that for most people, the maximum benefit from these drugs occurs at relatively low doses. The guidelines reiterate the importance of the step up/step down approach, and...

  • New study allays fear over inhaled steroids. Pedder, Cato // Pulse;11/10/2003, Vol. 63 Issue 45, p17 

    Reports on the results of the study examining the effects of inhaled corticosteroids in patients with asthma or chronic obstructive pulmonary disease (COPD) in the U.S. Tendency of COPD to lead to decrease in bone mineral density; Indication that the inhaled steroids slow lung function decline...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics